Mural Oncology Stock Price | MURA Stock Quote, News, and History
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period: 0% 0
Total Analysts: 1
Buy Ratings: 1 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 13.00 Median: 13.00 Highest: 13.00
- All
- Buy
- Hold
- Sell
- Yearly
- Quarterly
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 26 | - | 12 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -7.78 | -5.29 | -3.63 | -4.75 | -4.45 |
| P/E Ratio | -0.42 | -0.61 | -0.89 | -0.68 | -0.73 |
| EBIT | -140 | -147 | -160 | -220 | -256 |
| EBITDA | -137 | -133 | -145 | - | - |
| Net Profit | -131 | -142 | -156 | -217 | -251 |
| Net Profit Adjusted | - | - | - | - | - |
| Pre-Tax Profit | -131 | -142 | -156 | -217 | -251 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | - | - | - | - | - |
| Gross Income | - | - | - | - | - |
| Cash Flow from Investing | - | - | - | - | - |
| Cash Flow from Operations | - | - | - | - | - |
| Cash Flow from Financing | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 9.56 | 4.37 | 3.23 | - | - |
| Net Debt | -156 | -196 | -235 | - | - |
| Research & Development Exp. | 112 | 128 | 141 | 148 | 150 |
| Capital Expenditure | - | - | - | - | - |
| Selling, General & Admin. Exp. | - | - | - | - | - |
| Shareholder’s Equity | - | - | - | - | - |
| Total Assets | - | - | - | - | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 2 | 2 | 2 | 2 | 2 |
| Average Estimate | -1.950 USD | -1.970 USD | -2.020 USD | -7.780 USD | -5.290 USD |
| Year Ago | - | -3.073 USD | -3.567 USD | -12.430 USD | - |
| Publish Date | 8/13/2024 | 11/13/2024 | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 1 | 1 | 1 | 2 | 2 |
| Average Estimate | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD |
| Year Ago | - | 0 USD | 0 USD | 0 USD | - |
| Publish Date | 8/13/2024 | 11/13/2024 | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Mural Oncology PLC Registred Shs | 0.00 | 0.00 | USD |
| 2022 | Mural Oncology PLC Registred Shs | - | - | USD |
| 2021 | Mural Oncology PLC Registred Shs | - | - | USD |
*Yield of the Respective Date
Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.
| Owner | in % |
|---|---|
| Freefloat | 97.42 |
| The Vanguard Group, Inc. | 11.01 |
| Armistice Capital LLC | 9.80 |
| Armistice Capital LLC | 9.80 |
| Westfield Capital Management Co. LP | 9.15 |
| DUMAC, Inc. | 5.93 |
| Vanguard Group, Inc. (Subfiler) | 5.44 |
| Verition Fund Management LLC | 4.68 |
| Solas Capital Management LLC | 4.43 |
| Westfield Capital Management Co. LP | 4.39 |
| Alta Fundamental Advisers LLC | 4.27 |
| Harbor Small Cap Growth Fund | 3.46 |
| BlackRock Fund Advisors | 3.30 |
| Vanguard Total Stock Market ETF | 3.07 |
| Newtyn Management LLC | 2.95 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLnUq5hmq6SksKw%3D